Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Paclik, Daniela ^a   Danese, Silvio ^b   Berndt, Uta ^a   Wiedenmann, Bertram ^a   Dignass, Axel ^c   Sturm, Adreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; GALECTIN 4; SMALL INTERFERING RNA; BETA1 INTEGRIN; CALPAIN; CD3 ANTIGEN; CD7 ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL ISOLATION; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CULTURE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD29; ANTIGENS, CD3; ANTIGENS, CD7; APOPTOSIS; CALPAIN; CELL CYCLE; CELL PROLIFERATION; COLITIS; GALECTIN 4; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 49949103139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002629     Document Type: Article

References (39)

1. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205.
2. Strober W, Fuss I, Mannon PJ (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117: 514-521.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
4. Neurath MF, Mudter J (2006) Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 56: 293-303.
5. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, et al. (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23: 313-320.
6. Huflejt ME, Leffler H (2003) Galectin-4 in normal tissues and cancer. Glycoconj J 20: 247-255.
7. Nio J, Ken Y, Iwanaga T (2005) Differential cellular expression of galectin family mRNAs in the epithelial cells of the mouse digestive tract. J Histochem Cytochem 53: 1323-1334.
8. Pace KE, Lee C, Stewart PL, Baum LG (1999) Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 163: 3801-3811.
9. Sturm A, Lensch M, Andre S, Kaltner H, Wiedenmann B, et al. (2004) Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 173: 3825-3837.
10. Hokama A, Mizoguchi E, Sugimoto K, Shimomura Y, Tanaka Y, et al. (2004) Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20: 681-693.
11. Norton SD, Hovinen DE, Jenkins MK (1991) Il-2 Secretion and T-Cell Clonal Anergy Are Induced by Distinct Biochemical Pathways. J Immunol 146: 1125-1129.
12. Camby I, Le Mercier M, Lefranc F, Kiss R (2006) Galectin-1: a small protein with major functions. Glycobiology 16: 137R-157R.
13. Richter A, Lohning M, Radbruch A (1999) Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression. J Exp Med 190: 1439-1450.
14. Chen M, Won DJ, Krajewski S, Gottlieb RA (2002) Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 277: 29181-29186.
15. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, et al. (2003) Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170: 3631-3636.
16. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M (1995) Experimental Colitis Is Ameliorated by Inhibition of Nitric-Oxide Synthesis. Gastroenterology 108: A897.
17. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, et al. (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126: 520-528.
18. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-391.
19. Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
20. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, et al. (2006) Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis 13: 372-379.
21. Siegmund B, Sennello JA, Jones-Carson J, Gamboni-Robertson F, Lehr HA, et al. (2004) Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut 53: 965-972.
22. Santucci L, Fiorucci S, Rubinstein N, Mencarelli A, Palazzetti B, et al. (2003) Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124: 1381-1394.
23. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132: 52-65.
24. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, et al. (1999) Tumour necrosis factor a and interleukin 1 beta in relapse of Crohn's disease. Lancet 353: 459-461.
25. Korzenik JR, Podolsky DK (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5: 197-209.
26. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, et al. (2000) Blockade of interleukin 6 trans signaling suppresses, T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583-588.
27. Matarrese P, Tinari A, Mormone E, Bianco GA, Toscano MA, et al. (2005) Galectin-1 sensitizes resting human T lymphocytes to Fas (CD93)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem 280: 6969-6985.
28. Hahn HP, Pang M, He J, Hernandez JD, Yang RY, et al. (2004) Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 11: 1277-1286.
29. Stowell SR, Karmakar S, Stowell CJ, Dias-Baruffi M, McEver RP, et al. (2007) Human galectin-l,-2, and-4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109: 219-227.
30. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
31. Roth MS, Collins FS, Ginsburg D (1988) Sizing of the Human T-Cell Receptor Alpha-Locus and Detection of A Large Deletion in the Molt-4 Cell-Line. Blood 71: 1744-1747.
32. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, et al. (2000) Characterisation of acute routine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62: 240-248.
33. Braat H, McGuirk P, Ten Kate FJW, Huibregtse I, Dunne PJ, et al. (2007) Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule. Gut 56: 351-357.
34. Baumgart DC, Wiedenmann B, Dignass AU (2003) Biologic therapy of inflammatory bowel disease. Zeitschrift fur Gastroenterologie 41: 1017-1032.
35. Baumgart DC, Dignass AU (2004) Current biological therapies for inflammatory bowel disease. Current Pharmaceutical Design 10: 4127-4147.
36. Sturm A, Itoh J, Jacobberger JW, Fiocchi C (2002) p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest 109: 1481-1492.
37. Sturm A, Leite AZ, Danese S, Krivacic KA, West GA, et al. (2004) Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 53: 1624-1631.
38. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, et al. (2006) Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun 74: 4075-4082.
39. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, et al. (2002) Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122: 1428-1441.